

1 Association of COVID-19 with arterial and venous vascular diseases: a 2 population-wide cohort study of 48 million adults in England and Wales

3 **Short Title:** Vascular diseases after COVID-19

4 **Authors**

5 Rochelle Knight MSc^{1,2,3,4*}, Venexia Walker PhD^{1,4*}, Samantha Ip PhD^{5*}, Jennifer A Cooper PhD^{1,2},
6 Thomas Bolton PhD^{5,6,7,8}, Spencer Keene MSc^{5,6}, Rachel Denholm^{1,2,9}, Ashley Akbari MSc¹⁰, Hoda
7 Abbasizanjani PhD¹⁰, Fatemeh Torabi MSc¹⁰, Efosa Omigie BEng MSc¹¹, Sam Hollings PhD¹¹, Teri-
8 Louise North PhD¹, Renin Toms PhD¹, Emanuele Di Angelantonio FRCP^{5,6,12,13}, Spiros Denaxas
9 PhD^{14,15,16,17}, Johan H Thygesen¹⁴, Christopher Tomlinson MBBS¹⁴, Ben Bray MD¹⁸, Craig J Smith MD
10 MRCP^{19,20}, Mark Barber MD²¹, George Davey Smith MD FRS^{1,4}, Nishi Chaturvedi MD²², Cathie Sudlow
11 FRSE^{7,8}, William N Whiteley FRCP^{*23,24}, Angela Wood PhD^{*5,6,10,11,25}, Jonathan A C Sterne PhD^{*1,2,7}, for
12 the CVD-COVID-UK/COVID-IMPACT consortium and the Longitudinal Health and Wellbeing COVID-19
13 National Core Study.

- 14 1. Department of Population Health Sciences, Bristol Medical School, University of Bristol, Bristol,
15 UK.
- 16 2. NIHR Bristol Biomedical Research Centre, Bristol, UK.
- 17 3. NIHR Applied Research Collaboration West, Bristol, UK
- 18 4. MRC Integrative Epidemiology Unit, Bristol, UK
- 19 5. British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and
20 Primary Care, University of Cambridge, Cambridge, UK
- 21 6. National Institute for Health Research Blood and Transplant Research Unit in Donor Health and
22 Genomics, University of Cambridge, Cambridge, UK
- 23 7. BHF Data Science Centre
- 24 8. Health Data Research UK
- 25 9. Health Data Research UK South-West, Bristol, UK
- 26 10. Population Data Science, Health Data Research UK, Swansea University
- 27 11. NHS Digital
- 28 12. British Heart Foundation Centre of Research Excellence, University of Cambridge, Cambridge, UK
- 29 13. Health Data Research UK Cambridge, Wellcome Genome Campus and University of Cambridge,
30 Cambridge, UK
- 31 14. Institute of Health Informatics, University College London
- 32 15. Health Data Research UK, University College London, London, UK
- 33 16. NIHR University College London Hospitals Biomedical Research Centre, London, UK
- 34 17. BHF Accelerator, London, UK
- 35 18. School of Population Health and Environmental Sciences, King's College London
- 36 19. Geoffrey Jefferson Brain Research centre, Manchester Centre for Clinical Neurosciences,
37 Northern Care Alliance NHS Foundation Trust, Salford Royal Hospital, Salford
- 38 20. Division of Cardiovascular Sciences, University of Manchester
- 39 21. Glasgow Caledonian University
- 40 22. MRC Unit for Lifelong Health and Ageing at UCL, Institute of Cardiovascular Science, University
41 College London, London, U.K.
- 42 23. Centre for Clinical Brain Sciences, University of Edinburgh
- 43 24. Nuffield Department of Population Health University of Oxford
- 44 25. NIHR Cambridge Biomedical Research Centre

45 *Drs Walker, Knight and Ip contributed equally. Drs Whiteley, Wood, and Sterne contributed equally.

46 **Corresponding author**

47 Jonathan A C Sterne, Population Health Sciences, Bristol Medical School, University of Bristol, UK.

48 Email: jonathan.sterne@bristol.ac.uk
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

49 **Word count:** 3121

50

51 **Key points**

52 **Question**

53 Is COVID-19 associated with higher long-term incidence of vascular diseases?

54 **Findings**

55 In this cohort study of 48 million adults in England and Wales, COVID-19 was associated with higher
56 incidence, that declined with time since diagnosis, of both arterial thromboses [week 1: adjusted HR
57 [aHR] 21.7 (95% CI 21.0-22.4) weeks 27-49: aHR 1.34 (1.21-1.48)] and venous thromboembolism
58 [week 1: aHR 33.2 (31.3-35.2), weeks 27-49 1.80 (1.50-2.17)]. aHRs were higher, for longer, after
59 hospitalised than non-hospitalised COVID-19. The estimated excess number of arterial thromboses
60 and venous thromboembolisms was 10,500.

61 **Meaning**

62 Avoidance of COVID-19 infection through vaccination, and use of secondary preventive agents after
63 infection in high-risk patients, may reduce post-COVID-19 acute vascular diseases.

64 Abstract

65 **Importance:** The long-term effects of COVID-19 on the incidence of vascular diseases are unclear.

66 **Objective:** To quantify the association between time since diagnosis of COVID-19 and vascular
67 disease, overall and by age, sex, ethnicity, and pre-existing disease.

68 **Design:** Cohort study based on population-wide linked electronic health records, with follow up from
69 January 1st to December 7th 2020.

70 **Setting and participants:** Adults registered with an NHS general practice in England or Wales and
71 alive on January 1st 2020.

72 **Exposures:** Time since diagnosis of COVID-19 (categorised as 0-6 days, 1-2 weeks, 3-4, 5-8, 9-12, 13-
73 26 and 27-49 weeks since diagnosis), with and without hospitalisation within 28 days of diagnosis.

74 **Main outcomes and measures:** Primary outcomes were arterial thromboses (mainly acute
75 myocardial infarction and ischaemic stroke) and venous thromboembolic events (VTE, mainly
76 pulmonary embolism and lower limb deep vein thrombosis). We also studied other vascular events
77 (transient ischaemic attack, haemorrhagic stroke, heart failure and angina). Hazard ratios were
78 adjusted for demographic characteristics, previous disease diagnoses, comorbidities and
79 medications.

80 **Results:** Among 48 million adults, 130,930 were and 1,315,471 were not hospitalised within 28 days
81 of COVID-19. In England, there were 259,742 first arterial thromboses and 60,066 first VTE during
82 41.6 million person-years follow-up. Adjusted hazard ratios (aHRs) for first arterial thrombosis
83 compared with no COVID-19 declined rapidly from 21.7 (95% CI 21.0-22.4) to 3.87 (3.58-4.19) in
84 weeks 1 and 2 after COVID-19, 2.80 (2.61-3.01) during weeks 3-4 then to 1.34 (1.21-1.48) during
85 weeks 27-49. aHRs for first VTE declined from 33.2 (31.3-35.2) and 8.52 (7.59-9.58) in weeks 1 and 2
86 to 7.95 (7.28-8.68) and 4.26 (3.86-4.69) during weeks 3-4 and 5-8, then 2.20 (1.99-2.44) and 1.80
87 (1.50-2.17) during weeks 13-26 and 27-49 respectively. aHRs were higher, for longer after diagnosis,
88 after hospitalised than non-hospitalised COVID-19. aHRs were also higher among people of Black
89 and Asian than White ethnicity and among people without than with a previous event. Across the
90 whole population estimated increases in risk of arterial thromboses and VTEs were 2.5% and 0.6%
91 respectively 49 weeks after COVID-19, corresponding to 7,197 and 3,517 additional events
92 respectively after 1.4 million COVID-19 diagnoses.

93 **Conclusions and Relevance:** High rates of vascular disease early after COVID-19 diagnosis decline
94 more rapidly for arterial thromboses than VTEs but rates remain elevated up to 49 weeks after
95 COVID_19. These results support continued policies to avoid COVID-19 infection with effective
96 COVID-19 vaccines and use of secondary preventive agents in high-risk patients.

97

98 Introduction

99 Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of COVID-
100 19, induces a pro-thrombotic and pro-inflammatory state that may increase the risk of serious
101 thrombotic disorders.¹ Most previous studies suggest immediate marked increases in both arterial
102 (largely MI and stroke), and venous thromboembolic events (VTEs),²⁻⁸ although these might be
103 exaggerated due to universal testing for COVID-19 in all hospital admissions. However, few studies
104 have quantified long term vascular risks after diagnosis of COVID-19 or explored how these risks
105 differ by key characteristics such as age, sex, ethnicity, or pre-existing disease.

106 Anonymised population-scale linked primary and secondary care electronic health records (EHRs) for
107 the whole population of England and Wales were analysed to estimate the relative incidence of
108 major arterial thromboses and VTEs up to one year after COVID-19 diagnosis, compared with people
109 without COVID-19, accounting for multiple potential confounding factors. Variation in relative
110 incidence by COVID-related hospitalisation and demographic factors was examined.

111 **Methods**

112 **Population**

113 Pseudonymised data on adults alive and registered with a primary care general practice in England
114 or Wales on 1st January 2020 were accessed and analysed, within NHS Digital's secure, privacy
115 protecting Trusted Research Environment (TRE) Service for England and the SAIL databank for
116 Wales.^{9,10} The TRE for England includes primary care data (GPES data for Pandemic Planning and
117 Research, GDPDR) from 98% of general practices linked at individual-level to secondary care data
118 including all NHS hospital admissions, critical care, emergency department and outpatient episodes
119 (Hospital Episode Statistics and Secondary Uses Service data from 1997 onwards), COVID-19
120 laboratory testing data, national community drug dispensing data (NHS BSA Dispensed Medicines
121 from 2018) and death registrations. The SAIL databank includes data from hospital admissions,
122 mortality registers, primary care, COVID-19 test results, community dispensing, and critical care,
123 enabled through the C19_Cohort20 platform.¹¹

124 **COVID-19 diagnosis**

125 COVID-19 diagnosis was defined as a record of a positive COVID-19 polymerase chain reaction (PCR),
126 or antigen test, or a confirmed COVID-19 diagnosis in primary care or secondary care hospital
127 admission records and derived the earliest date on which COVID-19 was recorded (Supplementary
128 Table 1). 'Hospitalisation for COVID-19' was defined as a hospital admission record with confirmed
129 COVID-19 diagnosis in the primary position within 28 days of first COVID-19 diagnoses and 'COVID-
130 19 without hospitalisation' as a COVID-19 diagnosis without such hospitalisation.

131 **Outcomes**

132 Outcomes were defined using primary care, hospital admission and national death registry data
133 (Supplementary Table 2). Specialist clinician-verified SNOMED-CT, Read code and ICD-10 rule-based
134 phenotyping algorithms were used to define fatal or non-fatal: (i) arterial thromboses (myocardial
135 infarction (MI), ischaemic stroke (ischaemic or unclassified stroke, spinal stroke or retinal infarction),
136 and other non-stroke non-MI arterial thromboembolism); (ii) VTEs (pulmonary embolism (PE), lower
137 limb deep venous thrombosis (DVT), other DVT, portal vein thrombosis and intracranial venous
138 thrombosis (ICVT)); and (iii) other vascular events (transient ischaemic attack (TIA), haemorrhagic
139 stroke (intracerebral or subarachnoid haemorrhage), heart failure and angina).

140 **Potential confounding variables**

141 Primary and secondary care records up to 1st January 2020 were used to define ethnicity,
142 deprivation, smoking status and region. A large number of potentially confounding variables were
143 defined based on previous disease diagnoses, comorbidities and medications (Supplementary Table
144 3).

145 **Statistical Analyses**

146 Hazard ratios (HRs) were estimated for time since diagnosis of COVID-19 (categorised as 0-6 days, 1-
147 2 weeks, 3-4, 5-8, 9-12, 13-26 and 27-49 weeks since diagnosis), compared with follow up without or
148 before diagnosis of COVID-19 (reference group). Analyses used Cox regression models with calendar
149 time scale (starting on 1st January 2020), to account for rapid changes in incidence rates during the
150 pandemic, fitted separately by age group (categorised as <40, 40-59, 60-79 and ≥80 years on 1st
151 January 2020) and by population (England and Wales). Censoring was at the earliest of the date of
152 the outcome, death, or 7th December 2020 (the day before the UK COVID-19 vaccine rollout
153 started). For computational efficiency, analyses included all people with the outcome of interest or
154 with a record of COVID-infection, and a 10% randomly sampled subset of other people. Analyses
155 incorporated inverse probability weights with robust standard errors to account for this sampling.
156 Overall HRs were combined across age groups using inverse-variance weighted meta-analyses.

157 Crude; age, sex and region-adjusted; and maximally adjusted HRs were estimated: the latter
158 controlled for all the potential confounders listed in Supplementary Table 3. Where necessary in
159 subgroup analyses, potential confounders with ≤ 2 disease events at any level were excluded. In
160 subgroup analyses for which there were no outcome events in one or more time periods post-
161 COVID-19 diagnosis the time periods were collapsed into categories “1-4” and “>5” weeks since
162 COVID-19.

163 Separate analyses were conducted after hospitalised and non-hospitalised COVID-19. For the
164 combined arterial thrombosis and VTE outcomes, additional subgroup analyses were conducted by
165 sex, ethnicity and history of arterial thrombosis and VTE respectively. Because of the smaller
166 population size, analyses of Welsh data excluded the <40 years age group, were restricted to all
167 COVID-19 diagnoses and the combined arterial thrombosis and VTE outcomes, and were conducted
168 separately only by sex. Results were combined across the English and Welsh populations using
169 inverse-variance weighted meta-analyses. Further details of the statistical analyses are provided in
170 the supplementary material.

171 The average daily incidence of major arterial and venous events before or in the absence of COVID-
172 19 was calculated across the whole follow up period, separately in subgroups defined by age and
173 sex. These were multiplied by the maximally adjusted age- and sex-specific HR for that day to derive
174 the incidence on each day after COVID-19. A life table approach was used to calculate age- and sex-
175 specific cumulative risks over time with and without COVID-19 and latter was subtracted from the
176 former to derive the absolute excess risks over time after COVID-19, compared with no COVID-19
177 diagnosis. Overall absolute excess risk was estimated from a weighted sum of the age and sex-
178 specific excess risks, weighted by the proportions of people in age and sex strata within the COVID-
179 19 infected population in England during the follow-up period.

180 **Study oversight**

181 Approval was obtained from the Newcastle & North Tyneside 2 Research Ethics Committee
182 (20/NE/0161), the NHS Digital Data Access Request Service (DARS-NIC 381078-Y9C5K) and the British
183 Heart Foundation Data Science Centre CVD-COVID UK Approvals and Oversight Board.

184 Pseudonymised data was accessed and analysed within privacy protecting trusted research
185 environments. The analysis was performed according to a pre-specified analysis plan with
186 phenotyping and analysis code at github.com/BHFDSC/CCU002_01. Analyses used SQL, Python and
187 RStudio (Professional) Version 1.3.1093.1 driven by R Version 4.0.3 (2020-10-10).

188

189 Results

190 Among 44,964,486 people in the England population, 118,879 (264/100,000) were hospitalised with
191 COVID-19 and 1,248,810 (,2776/100,000) were not hospitalised within 28 days of their COVID-19
192 diagnosis (Table 1). Among 2,615,854 people in the Wales population 12,051 and 66,661
193 respectively were hospitalised and not hospitalised after COVID-19 (Supplementary Table 4).

194 The risk of non-hospitalised COVID-19 was higher in women than men (3,110 versus 2,428/100,000),
195 but the risk of hospitalised COVID-19 was higher in men than women (304 versus 226/100,000)
196 (Table 1). As expected, the risk of hospitalised COVID-19 increased markedly with increasing age,
197 from 28.3/100,000 at age 18-29 years to 1,944/100,000 at age 90+ years. By contrast the risk of non-
198 hospitalised COVID-19 was higher (3,816 and 4,749/100,000) in these youngest and oldest age
199 groups and lowest (1,450/100,000) in those aged 70-79 years. The risks of both hospitalised and
200 non-hospitalised COVID-19 increased with increasing index of multiple deprivation.

201 Numbers of arterial thromboses, VTEs and other vascular events before COVID-19 and after
202 hospitalised and non-hospitalised COVID-19, in the England population are shown in Table 2. Of
203 259,742 arterial thromboses, 2,246 and 5,150 were after hospitalised and non-hospitalised COVID-
204 19 respectively. Corresponding figures for VTEs were 60,066, 810 and 1,812. Most arterial
205 thromboses were either acute myocardial infarction (MI, 129,429) or ischaemic stroke (128,340) and
206 most VTEs were either pulmonary embolism (PE, 32,153) or lower limb deep vein thrombosis (DVT,
207 25,590). The proportion of strokes due to haemorrhage was as expected (9.2% after hospitalised
208 COVID-19 and 15% after non-hospitalised COVID-19). The total person-years of follow up in the
209 England population were 41,595,372 before COVID-19, 32,471 after hospitalised COVID-19 and
210 245,817 after non-hospitalised COVID-19. Corresponding figures in the Wales population were
211 2,383,967, 3,048 and 10,961.

212 Across outcomes and all time periods after COVID-19, maximally adjusted hazard ratios (aHRs) were
213 attenuated compared with unadjusted hazard ratios (Figure 1, Supplementary Table 5). aHRs for
214 acute myocardial infarction (AMI) declined rapidly from 17.2 (95% CI 16.3-18.1) in week 1 to 1.21
215 (1.03-1.41) in weeks 27-49. They were higher, for longer after diagnosis, after hospitalised compared
216 with non-hospitalised COVID-19: aHRs during weeks 27-49 were 1.39 (1.12-1.72) and 1.03 (0.83-
217 1.28) respectively (Supplementary Figure 1). aHRs for ischaemic stroke were higher than for MI: they
218 declined from 28.1 (26.8-29.4) in week 1 to 1.62 (1.42-1.86) in weeks 27-49, at which time they were
219 1.62 (1.33-1.98) and 1.33 (1.10-1.59) after hospitalised and non-hospitalised COVID-19 respectively.

220 Rates of DVT and PE were elevated for longer after diagnosis of COVID-19 than those for arterial
221 thromboses: aHRs compared with no COVID-19 were 4.80 (95% CI 4.03-5.73) and 10.5 (9.44-11.8)
222 respectively 3-4 weeks after diagnosis, declining to 1.62 (1.42-1.86) and 1.99 (1.49-2.65) in weeks
223 27-49, by which time aHRs were similar for hospitalised and non-hospitalised COVID-19. Overall
224 aHRs for haemorrhagic stroke declined to below 2 by 3-4 weeks after diagnosis, but peaked again
225 (aHR 4.85 [3.01-7.81]) 9-12 weeks after hospitalised COVID-19. aHRs for angina and heart failure
226 declined rapidly and were below 1.5 by 13-26 weeks after diagnosis.

227 For the first (of any) arterial thrombosis, aHRs compared with no COVID-19 declined rapidly from
228 21.7 (95% CI 21.0-22.4) to 3.87 (3.58-4.19) between the first and second weeks after COVID-19 to
229 2.80 (2.61-3.01) during weeks 3-4 and then more gradually to 1.34 (1.21-1.48) during weeks 27-49
230 (Figure 2, supplementary Table 6). aHRs were higher after hospitalised than non-hospitalised COVID-
231 19 from week 2 (6.60 [5.85-7.44] versus 2.65 [2.37-2.96]) onwards declining to 1.46 (1.26-1.70)
232 versus 1.21 (1.05-1.40) by weeks 27-49. During weeks 1-4 aHRs were greater in those with no prior
233 history of an arterial thrombosis (12.1 [11.5-12.8]), compared to those with a prior history (6.21
234 [5.30-7.27]), an effect that attenuated with duration of follow up. There were no consistent
235 differences between age groups. aHRs were marginally greater in males than females. aHRs were
236 greater in people of Black or Black British ethnicity (10.4 [95% CI 8.70-12.5] and 1.96 [1.60-2.41]

237 during weeks 1-4 and 5-49 respectively) and people of Asian or Asian British ethnicity (9.35 [8.48-
238 10.30] and 1.64 [1.43-1.89] respectively) than those of White ethnicity (7.66 [7.42-7.92] and 1.47
239 [1.40-1.53] respectively).

240 For the first VTE, aHRs after COVID-19 compared with no COVID-19 declined more gradually than
241 those for arterial thromboses, from 33.2 (95% CI 31.3-35.2) and 8.52 (7.59-9.58) in the first and
242 second weeks to 7.95 (7.28-8.68) and 4.26 (3.86-4.69) during weeks 3-4 and 5-8, then more
243 gradually to 2.20 (1.99-2.44) and 1.80 (1.50-2.17) during weeks 13-26 and 27-49 respectively (Figure
244 3, Supplementary Table 7). aHRs for venous events were substantial for the first 8 weeks following
245 hospitalised COVID-19 (11.2 [9.72-12.9] during weeks 5-8 then 5.40 [4.31-6.77], 2.63 [2.19-3.14] and
246 1.57 [1.14-2.16] during weeks 9-12, 13-26 and 27-49 respectively. Following non-hospitalised COVID-
247 19, aHRs were 2.56 (2.22-2.95), 2.22 (1.84-2.68), 1.98 (1.74-2.25) and 1.77 (1.38-2.27) during weeks
248 5-8, 9-12, 13-26 and 27-49 respectively. aHRs were greater in those without than with a prior history
249 of a venous event, but did not differ markedly between age groups. aHRs in males were greater than
250 those in females during weeks 1-4 after COVID-19. aHRs were higher in people of Black or Black
251 British ethnicity (18.0 [14.3-22.8] and 2.68 [1.94-3.70] during weeks 1-4 and 5-49 respectively) and
252 people of Asian or Asian British ethnicity (17.6 [14.2-21.8] and 4.05 [3.09-5.31] respectively) than
253 those of White ethnicity (10.1 [9.56-10.7] and 2.49 [2.32-2.66] respectively).

254 Absolute excess risks were generally greater in men and in older patients (Figure 4). Combining all
255 arterial thromboses, the excess risk 49 weeks after diagnosis of COVID-19 ranged from 2.3% and
256 1.7% respectively in men and women aged ≥ 80 years to 0.03% and 0.01% respectively in men and
257 women aged < 40 years (Figure 4). Combining all VTE events, the excess risk at 49 weeks ranged from
258 0.6% in men and women aged ≥ 80 years to 0.1% in men and women aged < 40 years. Excluding
259 events in the first 28 days approximately halved these absolute excess risks (Supplementary Figure
260 2). Across the whole population, the estimated absolute increases in the risk of arterial thromboses
261 and VTEs were 0.5% and 0.25% respectively. This corresponds to 7,200 and 3,500 additional arterial
262 thromboses and VTEs respectively after 1.4 million COVID-19 diagnoses.

263 Discussion

264 In this cohort of 48 million adults, markedly higher relative incidence of arterial thromboses in the
265 first weeks after COVID-19 diagnosis, relative to no COVID-19 diagnosis, declined rapidly. High
266 relative incidence of VTEs in the first weeks after COVID-19 diagnosis declined less rapidly than for
267 arterial thromboses, and remained 2-fold higher up to 49 weeks post COVID-19 diagnosis. For both
268 arterial thromboses and VTEs, relative incidence was higher, and remained elevated for longer, after
269 hospitalised than non-hospitalised COVID-19. Associations did not vary markedly by age or sex, but
270 were greater in people of Black or Asian ethnicity than those of White ethnicity, and in people
271 without than with a prior history of vascular events. By December 2020, COVID-19 led to over 10,500
272 additional arterial thromboses and VTEs in England and Wales.

273 As we included almost all of the adult English and Welsh populations, the results reflect the total
274 population impact of COVID-19 on the incidence of major vascular events, and are generalisable to
275 other settings with comprehensive healthcare. Linkage with primary care records and national
276 COVID-19 testing data allowed us to study vascular diseases after both hospitalised and non-
277 hospitalised COVID-19, and adjust for a wide range of potentially confounding factors. We used a
278 widely agreed set of codes in EHRs to identify arterial thromboses and VTEs recorded in the first
279 position in hospital and death records. The protocol was prespecified and all code lists are available.

280 Like other studies of vascular disease risk after COVID-19 infection,^{4,7,8,14} this study found that
281 incidence of arterial thromboses and VTEs was markedly elevated in the first 1-2 weeks after COVID-
282 19 diagnosis, and declined with time from diagnosis. Two self-controlled case series found that
283 excluding cases of arterial or venous events recorded on the first day of COVID-19 diagnosis
284 attenuated the early relative incidence associated with COVID-19.^{4,7} This may have been due to
285 ascertainment of COVID-19 at the time of hospitalisation for a vascular event, or to limited
286 resolution of date coding of COVID and vascular events in the same hospital admission.

287 Incidence of arterial thromboses and VTEs is also elevated after non-COVID-19 infections. In general,
288 the relative increases are greatest soon after infection and fall within a month towards baseline,
289 although elevated incidence of VTEs may persist for longer. These relative increase after other
290 infections was similar to this study's estimates 2 weeks after COVID-19 diagnosis.^{13,15-17}

291 Hospital admissions due to MI¹⁸ and stroke¹⁹ fell during the height of the COVID-19 pandemic in
292 England and Wales. This suggests any increase in hospitalisations for arterial thromboses or VTEs
293 after COVID-19 is small compared with the substantial reductions in diagnoses and healthcare use
294 during the early stages of the pandemic.

295 The estimates of the increased absolute risk of arterial thromboses and VTEs after a single COVID-19
296 infection are small, at most 2.3% in men and 1.7% in women aged ≥ 80 years. Nonetheless, the large
297 number of COVID-19 infections in England and Wales during 2020 is likely to have caused a
298 substantial additional burden of arterial thromboses and VTEs. Preventive strategies after COVID-19
299 might be important at a population level, if they do not substantially increase the risk of adverse
300 events such as bleeding. Observational studies suggest a protective effect of statin and blood
301 pressure lowering.^{20,21} Randomised trials of short courses of antithrombotic interventions with a low
302 risk of harm might be the next step, although the largest study of aspirin in patients hospitalised
303 with COVID-19 showed the reduction in thrombotic events was similar to the increase in
304 haemorrhagic events.²² Studies of aspirin in non-hospitalised patients with COVID-19 are ongoing. To
305 avoid post-COVID-19 thrombotic events, policy responses should include avoiding severe COVID-19
306 infection through population-wide use of effective COVID-19 vaccines, and use of existing secondary
307 preventative agents in patients with a prior history of stroke or MI.

308 This study has several limitations. First, the survival analyses allowed for variations in diagnoses with
309 calendar time, so should control for the reductions in hospital attendance the period of maximum

310 disruption (March and April 2020). However, some vascular events not have been recorded either
311 because patients died in nursing homes with few diagnostic resources, or were so unwell that MI,
312 stroke, PE or DVT diagnoses would have been difficult. Second, patients may have avoided
313 healthcare after minor vascular events because of fear of COVID-19. If this was more likely in people
314 without COVID-19, then estimated hazard ratios would have been biased upwards. Third, because
315 the English primary care dataset did not include information on PE and DVT, the incidence of milder
316 venous events may have been underestimated.

317 Fourth, we had limited resolution to determine the date order of COVID diagnosis and arterial
318 thromboses or VTE events for some hospitalised patients. Some patients hospitalised with a vascular
319 event either developed a nosocomial infection or had a COVID-19 diagnosis after routine testing on
320 admission. For some patients, a raised troponin with COVID-19 may have led to a diagnosis of MI.¹²
321 Therefore the very high hazard ratios within one week of COVID-19 diagnosis may have been
322 inflated by reverse causality. Fifth, there was under-ascertainment of COVID-19 infection before
323 testing for SARS-CoV-2 became widely available for mild or asymptomatic infections. Such
324 underdiagnosis would bias estimated post-COVID hazard ratios towards the null.

325 Sixth, unmeasured confounding may explain some findings, since there is a substantial overlap
326 between risk factors for vascular disease and COVID-19. Risk factors for vascular events (e.g. body
327 mass index) are not systematically recorded for all patients, and are subject to measurement error.
328 The difference between adjusted and unadjusted hazard ratios was more marked longer after
329 COVID-19 diagnosis: the hazard ratios for major arterial events more than 13 weeks (HR 1.3) after
330 diagnosis could be due to unmeasured confounding. However the higher hazard ratios for venous
331 events after 13 weeks are less plausibly explained by unmeasured confounding, and are consistent
332 with the risk of venous events after other infections.¹³

333 In conclusion, substantial increases in the relative incidence of arterial thromboses and VTE events
334 1-2 weeks after diagnosis of COVID-19 decline with time since diagnosis, although doubling of the
335 incidence of VTE events persisted up to 49 weeks after diagnosis. These results support continued
336 policies to avoid COVID-19 infection with effective COVID-19 vaccines and use of secondary
337 preventive agents in high-risk patients.

338

339 **Data sharing**

340 Data used in this study are available in NHS Digital's Trusted Research Environment (TRE) for
341 England, but as restrictions apply they are not publicly available
342 ([https://digital.nhs.uk/coronavirus/coronavirus-data-services-updates/trusted-research-](https://digital.nhs.uk/coronavirus/coronavirus-data-services-updates/trusted-research-environment-service-for-england)
343 [environment-service-for-england](https://digital.nhs.uk/coronavirus/coronavirus-data-services-updates/trusted-research-environment-service-for-england)). The CVD-COVID-UK/COVID-IMPACT programme led by the BHF
344 Data Science Centre (<https://www.hdruc.ac.uk/helping-with-health-data/bhf-data-science-centre/>)
345 received approval to access data in NHS Digital's TRE for England from the Independent Group
346 Advising on the Release of Data (IGARD) ([https://digital.nhs.uk/about-nhs-digital/corporate-](https://digital.nhs.uk/about-nhs-digital/corporate-information-and-documents/independent-group-advising-on-the-release-of-data)
347 [information-and-documents/independent-group-advising-on-the-release-of-data](https://digital.nhs.uk/about-nhs-digital/corporate-information-and-documents/independent-group-advising-on-the-release-of-data)) via an application
348 made in the Data Access Request Service (DARS) Online system (ref. DARS-NIC-381078-Y9C5K)
349 (<https://digital.nhs.uk/services/data-access-request-service-dars/dars-products-and-services>). The
350 CVD-COVID-UK/COVID-IMPACT Approvals & Oversight Board
351 (<https://www.hdruc.ac.uk/projects/cvd-covid-uk-project/>) subsequently granted approval to this
352 project to access the data within the TRE for England and the Secure Anonymised Information
353 Linkage (SAIL) Databank. The de-identified data used in this study was made available to accredited
354 researchers only.

355 Data used in this study are available in the SAIL Databank at Swansea University, Swansea, UK, but as
356 restrictions apply they are not publicly available. All proposals to use SAIL data are subject to review
357 by an independent Information Governance Review Panel (IGRP). Before any data can be accessed,
358 approval must be given by the IGRP. The IGRP gives careful consideration to each project to ensure
359 proper and appropriate use of SAIL data. When access has been granted, it is gained through a
360 privacy protecting data safe haven and remote access system referred to as the SAIL Gateway. SAIL
361 has established an application process to be followed by anyone who would like to access data via
362 SAIL at <https://www.saildatabank.com/application-process>.

363 **Acknowledgements**

364 This study makes use of de-identified data held in NHS Digital's Trusted Research Environment for
365 England and made available via the BHF Data Science Centre's CVD-COVID-UK/COVID-IMPACT
366 consortium. This work uses data provided by patients and collected by the NHS as part of their care
367 and support. We would also like to acknowledge all data providers who make health relevant data
368 available for research.

369 This study makes use of anonymised data held in the Secure Anonymised Information Linkage (SAIL)
370 Databank. This work uses data provided by patients and collected by the NHS as part of their care
371 and support. We would also like to acknowledge all data providers who make anonymised data
372 available for research. We wish to acknowledge the collaborative partnership that enabled
373 acquisition and access to the de-identified data, which led to this output. The collaboration was led
374 by the Swansea University Health Data Research UK team under the direction of the Welsh
375 Government Technical Advisory Cell (TAC) and includes the following groups and organisations: the
376 SAIL Databank, Administrative Data Research (ADR) Wales, Digital Health and Care Wales (DHCW),
377 Public Health Wales, NHS Shared Services Partnership (NWSSP) and the Welsh Ambulance Service
378 Trust (WAST). All research conducted has been completed under the permission and approval of the
379 SAIL independent Information Governance Review Panel (IGRP) project number 0911.

380 **Author contributions**

381 WW conceived the study. WW, AW, RD, JAC, CS and JACS drafted the protocol. JACS, AW, VW, JAC
382 and RD designed the statistical analyses. RK, VW, SI, TB, SK, AA, HA, FT, EO, SH, SD, JHT and CT
383 developed codelists and derived datasets. SD, JHT and CT created electronic health record
384 phenotyping algorithms for hospitalised and non-hospitalised COVID-19. RK, VW, SI, JAC, TB, SK, RD,

385 AA, HA, FT, TLN, RT, SD, JHT, CT and AW conducted statistical analyses. JACS, WW, AW, VW, RK and
386 SI produced the first draft of the manuscript. CS is Director of the BHF Data Science Centre and
387 coordinated approvals for and access to data within the NHS Digital TRE and the SAIL Databank TRE
388 for CVD-COVID-UK/COVID-IMPACT. All authors critically appraised the manuscript for important
389 intellectual content and contributed to the final draft of the manuscript.

390 **Funding**

391 This work was funded by the Longitudinal Health and Wellbeing COVID-19 National Core Study,
392 which was established by the UK Chief Scientific Officer in October 2020 and funded by UK Research
393 and Innovation (grant references MC_PC_20030 and MC_PC_20059), by the British Heart
394 Foundation as part of the BHF Data Science Centre led by HDR UK (BHF grant number
395 SP/19/3/34678), by the Data and Connectivity National Core Study, led by Health Data Research UK
396 in partnership with the Office for National Statistics and funded by UK Research and
397 Innovation (grant reference MC_PC_20058), and by the CONVALESCENCE study of long COVID, which
398 is funded by NIHR/UKRI. This work uses data provided by patients and collected by the NHS as part
399 of their care and support. We would also like to acknowledge all data providers who make
400 anonymised data available for research. This work was supported by the Con-COV team funded by
401 the Medical Research Council (grant number: MR/V028367/1). This work was supported by Health
402 Data Research UK, which receives its funding from HDR UK Ltd (HDR-9006) funded by the UK Medical
403 Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research
404 Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish
405 Government Health and Social Care Directorates, Health and Social Care Research and Development
406 Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation
407 (BHF) and the Wellcome Trust. This work was supported by core funding from the: British Heart
408 Foundation (BHF; RG/13/13/30194; RG/18/13/33946), BHF Cambridge CRE (RE/13/6/30180) and
409 NIHR Cambridge Biomedical Research Centre (BRC-1215-20014) [*]. This work was supported by the
410 ADR Wales programme of work. The ADR Wales programme of work is aligned to the priority themes
411 as identified in the Welsh Government's national strategy: Prosperity for All. ADR Wales brings
412 together data science experts at Swansea University Medical School, staff from the Wales Institute
413 of Social and Economic Research, Data and Methods (WISERD) at Cardiff University and specialist
414 teams within the Welsh Government to develop new evidence which supports Prosperity for All by
415 using the SAIL Databank at Swansea University, to link and analyse anonymised data. ADR Wales is
416 part of the Economic and Social Research Council (part of UK Research and Innovation) funded ADR
417 UK (grant ES/S007393/1). This work was supported by the Wales COVID-19 Evidence Centre, funded
418 by Health and Care Research Wales. SI was funded by a BHF-Turing Cardiovascular Data Science
419 Award (BCDSA\100005) and is funded by a University College London FB Cancer Research UK Award
420 (C18081/A31373). RK, JAC and JACS were supported by the NIHR Bristol Biomedical Research Centre.
421 RK, VW GDS were supported by the MRC Integrative Epidemiology Unit at the University of Bristol.
422 RK was supported by NIHR ARC West. RD and JACS were supported by Health Data Research UK. SK
423 is funded by the NIHR Blood and Transplant Research Unit in Donor Health and Genomics (NIHR
424 BTRU-2014-10024). TM was funded by the NIHR Blood and Transplant Research Unit in Donor Health
425 and Genomics (NIHR BTRU-2014-10024). AMW is part of the BigData@Heart Consortium, funded by
426 the Innovative Medicines Initiative-2 Joint Undertaking under grant agreement No 116074 and was
427 supported by the BHF-Turing Cardiovascular Data Science Award (BCDSA\100005). WW is supported
428 by the Chief Scientist's Office (CAF/01/17). CS, CS, MB AW and WW are supported by Stroke
429 Association (SA CV 20\100018).

430 *The views expressed are those of the author(s) and not necessarily those of the NIHR or the
431 Department of Health and Social Care.

432 **Conflicts of interest**

433 WW is supported by the Chief Scientist's Office (CAF/01/17) and Stroke Association (SA CV
434 20100018). WW has given expert testimony to UK courts. WW served on an advisory board
435 for Bayer. NC receives funds from AstraZeneca to support membership of Data Safety and
436 Monitoring Committees for clinical trials.

437

438 References

- 439 1 Loo J, Spittle DA, Newnham M. COVID-19, immunothrombosis and venous
440 thromboembolism: biological mechanisms. *Thorax* 2021; **76**: 412–20.
- 441 2 Bilaloglu S, Aphinyanaphongs Y, Jones S, Iturrate E, Hochman J, Berger JS. Thrombosis in
442 Hospitalized Patients With COVID-19 in a New York City Health System. *JAMA* 2020; **324**:
443 799–801.
- 444 3 Nannoni S, Groot R de, Bell S, Markus HS. Stroke in COVID-19: A systematic review and meta-
445 analysis: <https://doi.org/10.1177/1747493020972922> 2020; **16**: 137–49.
- 446 4 Hippisley-Cox J, Patone M, Mei XW, *et al.* Risk of thrombocytopenia and thromboembolism
447 after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study.
448 *BMJ* 2021; **374**: n1931.
- 449 5 Suh YJ, Hong H, Ohana M, *et al.* Pulmonary Embolism and Deep Vein Thrombosis in COVID-
450 19: A Systematic Review and Meta-Analysis. *Radiology* 2020; **298**: E70–80.
- 451 6 Tan BK, Mainbourg S, Friggeri A, *et al.* Arterial and venous thromboembolism in COVID-19: a
452 study-level meta-analysis. *Thorax* 2021; **76**: 970–9.
- 453 7 Katsoularis I, Fonseca-Rodríguez O, Farrington P, Lindmark K, Connolly A-MF. Risk of acute
454 myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled
455 case series and matched cohort study. *Lancet* 2021; **398**: 599–607.
- 456 8 Modin D, Claggett B, Sindet-Pedersen C, *et al.* Acute COVID-19 and the Incidence of Ischemic
457 Stroke and Acute Myocardial Infarction. *Circulation*. 2020; **142**: 2080–2.
- 458 9 Jones KH, Ford DV, Thompson S, Lyons R. A Profile of the SAIL Databank on the UK Secure
459 Research Platform. *Int J Popul Data Sci* 2019; **4**. DOI:10.23889/IJPDS.V4I2.1134.
- 460 10 Wood A, Denholm R, Hollings S, *et al.* Linked electronic health records for research on a
461 nationwide cohort of more than 54 million people in England: Data resource. *BMJ* 2021; **373**.
462 DOI:10.1136/bmj.n826.
- 463 11 Lyons J, Akbari A, Torabi F, *et al.* Understanding and responding to COVID-19 in Wales:
464 protocol for a privacy-protecting data platform for enhanced epidemiology and evaluation of
465 interventions. *BMJ Open* 2020; **10**. DOI:10.1136/BMJOPEN-2020-043010.
- 466 12 Long B, Brady WJ, Koyfman A, Gottlieb M. Cardiovascular complications in COVID-19. *Am. J.*
467 *Emerg. Med.* 2020; published online April 18. DOI:10.1016/j.ajem.2020.04.048.
- 468 13 Clayton T, Gaskin M, Meade T. Recent respiratory infection and risk of venous
469 thromboembolism: case-control study through a general practice database. *Int J Epidemiol*
470 2011; **40**: 819–27.
- 471 14 Al-Aly Z. One-year Risks and Burdens of Incident Cardiovascular Disease in COVID-19:
472 Cardiovascular Manifestations of Long COVID. 2021; published online Oct 5.
473 DOI:10.21203/RS.3.RS-940278/V1.
- 474 15 Kwong JC, Schwartz KL, Campitelli MA, *et al.* Acute Myocardial Infarction after Laboratory-
475 Confirmed Influenza Infection. *N Engl J Med* 2018; **378**: 345–53.
- 476 16 Cowan LT, Lutsey PL, Pankow JS, Cushman M, Folsom AR. Hospitalization with infection and
477 incident venous thromboembolism: The ARIC study. *Thromb Res* 2017; **151**: 74–8.
- 478 17 Rogers MAM, Levine DA, Blumberg N, Flanders SA, Chopra V, Langa KM. Triggers of
479 Hospitalization for Venous Thromboembolism. *Circulation* 2012; **125**: 2092–9.
- 480 18 Mafham MM, Spata E, Goldacre R, *et al.* COVID-19 pandemic and admission rates for and

- 481 management of acute coronary syndromes in England. *Lancet* 2020; **396**: 381–9.
- 482 19 Douiri A, Muruet W, Bhalla A, *et al.* Stroke Care in the United Kingdom During the COVID-19
483 Pandemic. *Stroke* 2021; : 2125–33.
- 484 20 Spiegeleer A De, Bronselaer A, Teo JT, *et al.* The Effects of ARBs, ACEis, and Statins on Clinical
485 Outcomes of COVID-19 Infection Among Nursing Home Residents. *J Am Med Dir Assoc* 2020;
486 **21**: 909.
- 487 21 Chow R, Im J, Chiu N, *et al.* The protective association between statins use and adverse
488 outcomes among COVID-19 patients: A systematic review and meta-analysis. *PLoS One* 2021;
489 **16**: e0253576.
- 490 22 Horby PW, Pessoa-Amorim G, Staplin N, *et al.* Aspirin in patients admitted to hospital with
491 COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *medRxiv* 2021; :
492 2021.06.08.21258132.
- 493
- 494

495 **Table 1: Number of patients analysed in the English Trusted Research Environment, and the**
 496 **numbers of people (risk per 100,000 during follow up) who were and were not hospitalised within**
 497 **28 days of diagnosis of COVID-19.**

Characteristic		All	Number diagnosed with COVID-19 (risk per 100,000)	
			Hospitalised	Non-hospitalised
All		44,964,486	118,879 (264)	1,248,180 (2776)
Sex	Male	22,003,234	66,954 (304)	534,198 (2428)
	Female	22,961,252	51,925 (226)	713,982 (3110)
Age	18 - 29	8,185,993	2,315 (28.3)	312,359 (3,816)
	30 - 39	8,088,594	4,754 (58.8)	230,993 (2,856)
	40 - 49	7,384,405	8,951 (121)	215,874 (2,923)
	50 - 59	7,709,556	15,806 (205)	218,836 (2,839)
	60 - 69	5,920,117	18,755 (317)	117,140 (1,979)
	70 - 79	4,723,368	26,205 (555)	68,469 (1,450)
	80 - 89	2,374,255	30,852 (1,299)	57,048 (2,403)
	90+	578,198	11,241 (1,944)	27,461 (4,749)
Ethnicity	Asian or Asian British	3,594,845	13,761 (383)	160,479 (4,464)
	Black or Black British	1,540,990	5,748 (373)	37,625 (2,442)
	Mixed	678,232	1,504 (222)	19,121 (2,819)
	Other Ethnic Groups	1,455,251	2,795 (192)	25,466 (1,750)
	White	36,131,134	93,871 (260)	980,990 (2,715)
	Unknown	1,254,798	929 (74.0)	19,377 (1544)
	Missing	309,236	271 (87.6)	5,122 (1656)
Index of Multiple Deprivation	1 – 2 (most deprived)	8,817,841	33,170 (376)	316,779 (3,592)
	3 - 4	9,173,504	26,553 (289)	261,364 (2,849)
	5 - 6	9,035,766	21,500 (238)	231,658 (2,564)
	7 – 8	8,825,196	19,793 (224)	226,234 (2,564)
	9 – 10 (least deprived)	8,571,714	16,850 (197)	199,733 (2,330)
	Missing	540,465	1,013 (187)	12,412 (2,297)
Smoking status	Current	7,746,609	8,776 (113)	151,693 (1,958)
	Former	10,440,342	46,595 (446)	278,105 (2,664)
	Never	24,875,152	61,968 (249)	755,621 (3,038)
	Missing	1,902,383	1,540 (81)	62,761 (3,299)
Medical history	Arterial event(s)	1,877,562	25,629 (1,365)	54,636 (2,910)
	Venous event(s)	629,769	7,573 (1,203)	20,049 (3,184)
Number of medications	0	22,262,206	15,724 (70.6)	591,154 (2,655)
	1 - 5	20,399,092	64,583 (317)	571,391 (2,801)
	6+	2,303,188	38,572 (1,675)	85,635 (3,718)
Number of diagnoses	0	32,831,142	50,791 (155)	864,717 (2,634)
	1 - 5	11,941,404	63,667 (533)	374,473 (3,136)
	6+	191,940	4,421 (2,303)	8,990 (4,684)
Region	North West	5,782,507	22,632 (391)	244,767 (4,233)
	South East	6,742,942	12,550 (186)	115,639 (1,715)
	London	7,266,911	19,524 (269)	135,530 (1,865)
	East of England	4,184,375	8,774 (210)	67,173 (1,605)
	South West	3,629,924	5,066 (140)	57,517 (1,585)
	Missing	3,422,062	6,441 (188)	67,141 (1,962)
	Yorkshire and the Humber	4,390,661	14,733 (336)	184,983 (4,213)
	East Midlands	3,236,271	8,701 (269)	110,496 (3,414)
	West Midlands	4,588,617	14,796 (322)	195,674 (4,264)
	North East	1,720,216	5,662 (329)	69,260 (4,026)

498

499 **Table 2. Numbers of arterial thrombotic, venous thromboembolic and other vascular events in the**
500 **English Trusted Research Environment before and after diagnosis of COVID-19.**


	No COVID-19	After hospitalised COVID-19	After non-hospitalised COVID-19	Total
Arterial thromboses				
First arterial thrombosis	252,326	2,246	5,170	259,742
Acute myocardial infarction	126,216	1,001	2,212	129,429
Ischaemic stroke	124,157	1,278	2,905	128,340
Other arterial embolism	5,535	62	223	5,820
Venous thromboembolic events				
First venous thromboembolism	57,444	810	1,812	60,066
Pulmonary embolism	30,348	579	1,226	32,153
Lower limb deep vein thrombosis	24,850	211	529	25,590
Other deep vein thrombosis	1,883	23	62	1,968
Portal vein thrombosis	513	<10	18	531
Intracranial venous thrombosis	678	<10	21	699
Other vascular events				
Heart failure	241,912	2,280	3,722	247,914
Angina	192,663	805	1,907	195,375
Transient ischaemic attack	62,124	276	789	63,189
Subarachnoid or intracranial haemorrhage	16,336	129	524	16,989

501

502


503

504 **Figure 1. Age/sex/region adjusted and maximally adjusted hazard ratios (log scale) for different**
 505 **arterial thrombotic, and venous thromboembolic and other vascular events by time since**
 506 **diagnosis of COVID-19.**




507

508 **Figure 2 Hazard ratios (log scale) for first arterial event after COVID-19 by time since diagnosis, overall and stratified by whether hospitalised with**
 509 **COVID-19, prior history of an arterial event, age, sex and ethnicity.**




510

511 **Figure 3 Hazard ratios for first venous event after COVID-19 by time since diagnosis, overall and stratified by whether hospitalised with COVID-19, prior**
 512 **history of an venous event, age, sex and ethnicity.**



513

514 **Figure 4. Estimated absolute increase in risk of arterial and venous events over time since diagnosis of COVID-19, compared with no COVID-19 diagnosis.**



515

516

517 **Supplementary Material**

518 **Additional details of statistical methods**

519 In general, we estimated hazard ratios using separate models for age group and, in the relevant analyses, for hospitalised and non-hospitalised COVID-19.
520 Overall results were then derived by combining hazard ratios across age groups using inverse-variance meta-analysis. The same set of covariates was
521 adjusted for in each age group before results were combined. In some analyses, limited numbers of outcome events after COVID-19 meant that the younger
522 age groups had to be combined in order to fit maximally adjusted models. For some models examining outcomes after hospitalised COVID-19, all age groups
523 had to be combined because small numbers of outcome events after hospitalised COVID-19 made it impossible to identify a set of covariates that could be
524 adjusted for across all groups, and/or some regions had to be merged.

525

526

527 **Supplementary Table 1. Derivation of COVID-19 variables in the English NHS Digital TRE and Welsh SAIL Databank TRE environments.**

528 All codelists are available in the GitHub for England: https://github.com/BHFDSC/CCU002_01/tree/main/england/phenotypes
 529 and similarly for Wales where Read codes were used for primary care: https://github.com/BHFDSC/CCU002_01/tree/main/Wales/phenotypes

530

Variable	Data Sources (NHS England)	Data Sources (SAIL Databank)	Description	Variable name in analysis code
Exposure				
COVID-19 diagnosis date	SGSS, GDPPR, deaths registry, HES APC, HES CC, CHESS, SUS	PATD (Pillar 1 & 2), PEDW, WLGP	Minimum date of confirmed COVID-19 event post index date. A record of a positive COVID-19 PCR antigen test or a record of confirmed diagnosis in primary care general practice or secondary care hospital admission records.	exp_confirmed_covid19_date
COVID-19 infection severity	SGSS, GDPPR, deaths registry, HES APC, HES CC, CHESS, SUS	PATD (Pillar 1 & 2), PEDW, WLGP	COVID-19 infection with hospitalisation was defined as a hospital admission record with confirmed COVID-19 diagnosis in the primary position within 28 days of first COVID-19 infection. COVID-19 infection without hospitalisation was defined as a confirmed COVID-19 diagnosis in the primary position within 28 days of first COVID-19 infection without a hospital admission record.	exp_confirmed_covid_phenotype

531 Acronyms: GDPPR (General Practice Extraction Service (GPES) Data for pandemic planning and research), HES (Hospital Episode Statistics), APC (Admitted Patient Care), , ADDE (Annual District
 532 Death Extract), PEDW (Patient Episode Dataset for Wales), WLGP (Welsh Longitudinal GP Dataset - Welsh Primary Care), PATD (COVID-19 Test Results), CHESS (COVID-19 Hospitalisation in
 533 England Surveillance System), SGSS (Covid-19 Second Generation Surveillance System).

534

535 **Supplementary Table 2. Derivation of major outcomes in the English NHS Digital TRE and Welsh SAIL Databank TRE environments.**

536 All codelists are available in the GitHub for England https://github.com/BHFDSC/CCU002_01/tree/main/england/phenotypes
 537 and similarly for Wales where Read codes were used for primary care: https://github.com/BHFDSC/CCU002_01/tree/main/Wales/phenotypes
 538

Outcome	Data Sources (NHS Digital)	Data Sources (SAIL Databank)	Description	Variable name in analysis code
Arterial thromboses				
Myocardial infarction	GDPPR, HES APC, deaths registry	WLGP, PEDW, ADDE	Earliest recorded date of primary care event or consultation, admission to hospital (coded as primary cause), or death (coded as underlying cause).	out_AMI
Ischaemic stroke*	GDPPR, HES APC, deaths registry	WLGP, PEDW, ADDE	Earliest recorded date of primary care event or consultation, admission to hospital (coded as primary cause), or death (coded as underlying cause).	out_stroke_isch
Other arterial thromboembolism	HES APC, deaths registry	PEDW, ADDE	Earliest recorded date of admission to hospital (coded as primary cause of the care episode), or death (coded as underlying cause).	out_other_arterial_embolism
Venous thromboembolic events				
Pulmonary embolism	HES APC, deaths registry	PEDW, ADDE	Earliest recorded date of admission to hospital (coded as primary cause of the care episode), or death (coded as underlying cause).	out_PE
Lower limb deep vein thrombosis	HES APC, deaths registry	PEDW, ADDE	Earliest recorded date of admission to hospital (coded as primary cause of the care episode), or death (coded as underlying cause).	out_DVT_DVT, out_DVT_pregnancy
Other deep vein thrombosis	HES APC, deaths registry	PEDW, ADDE	Earliest recorded date of admission to hospital (coded as primary cause of the care episode), or death (coded as underlying cause).	out_other_DVT
Portal vein thrombosis	HES APC, deaths registry	PEDW, ADDE	Earliest recorded date of admission to hospital (coded as primary cause of the care episode), or death (coded as underlying cause).	out_portal_vein_thrombosis
Intracranial venous thrombosis	HES APC, deaths registry	PEDW, ADDE	Earliest recorded date of admission to hospital (coded as primary cause of the care episode), or death (coded as underlying cause).	out_ICVT, out_ICVT_pregnancy
Other vascular events				
Intracranial or subarachnoid haemorrhage	HES APC, deaths registry	PEDW, ADDE	Earliest recorded date of admission to hospital (coded as primary cause of the care episode), or death (coded as underlying cause).	out_stroke_SAH_HS
Heart failure	GDPPR, HES APC, deaths registry	WLGP, PEDW, ADDE	Earliest recorded date of primary care event or consultation, admission to hospital (coded as primary cause), or death (coded as underlying cause).	out_HF
Angina	GDPPR, HES APC, deaths registry	WLGP, PEDW, ADDE	Earliest recorded date of primary care event or consultation, admission to hospital (coded as primary cause), or death (coded as underlying cause).	out_angina
Transient ischemic attack	GDPPR, HES APC, deaths registry	WLGP, PEDW, ADDE	Earliest recorded date of primary care event or consultation, admission to hospital (coded as primary cause), or death (coded as underlying cause).	out_stroke_TIA

539 Acronyms: GDPPR (General Practice Extraction Service (GPES) Data for pandemic planning and research), HES (Hospital Episode Statistics), APC (Admitted Patient Care), , ADDE (Annual District
 540 Death Extract), PEDW (Patient Episode Dataset for Wales), WLGP (Welsh Longitudinal GP Dataset - Welsh Primary Care), PATD (COVID-19 Test Results), CHESS (COVID-19 Hospitalisation in
 541 England Surveillance System), SGSS (Covid-19 Second Generation Surveillance System).
 542

543 **Supplementary Table 3. Derivation of covariates in the English NHS Digital TRE and Welsh SAIL Databank TRE environments.**

544 All codelists are available in the GitHub for England: github.com/BHFDSC/CCU002_01/tree/main/england/phenotypes
 545 and similarly for Wales where Read codes were used for primary care: https://github.com/BHFDSC/CCU002_01/tree/main/Wales/phenotypes
 546

Variable	Data Sources (NHS England)	Data Sources (SAIL Databank)	Description	Variable name in analysis code
Demographic characteristics				
Patient pseudoidentifier	All	All	Patient pseudoidentifier	NHS_NUMBER_DEID
death date	GDPPR, HES APC, deaths registry	C19_Cohort20 (WSD, ADDE, ADDD, CDDS)	Earliest date of death recorded in specified data sources	death_date
sex	GDPPR, HES APC, HES OP, HES AE	C19_Cohort20 (WSD)	Binary indicator for male or female (most recent record prior to index date and will initially select from primary care if possible)	cov_sex
age	GDPPR, HES APC, HES OP, HES AE	C19_Cohort20 (WSD)	Age in years calculated on index date (will initially select from primary care if possible)	cov_age
ethnicity	GDPPR, HES APC, HES OP, HES AE	CCDS, CVVD, EDDS, ICNC, MIDS, NCCH, OPRD, PEDW, WASD	Patient ethnicity (most recent record prior to index date from primary care - Black or Black British, Asian or Asian British, Other, Mixed, Missing, Unknown)	cov_ethncity
smoking status	GDPPR	WLGP	Most recent smoking status (Smoker, Ex-smoker, Never-smoker) prior to index date	cov_smoking_status
deprivation	English indices of deprivation year 2019	C19_Cohort20 (WSD, PEDW)	Most recent decile of deprivation prior to index date, defined using IMD	cov_deprivation
region of residence	English indices of deprivation year 2019	N/A	Most recent residence prior to index date (East of England, London, Midlands, NE and Yorkshire, North West, South East, South West, Scotland, Wales)	cov_region
Medications				
antiplatelet	primary care medications	WDDS	Binary indicator for antiplatelet medication with at least one prescription within 3 months prior to index date, defined using drug use	cov_antiplatelet_meds
lipid lowering	primary care medications	WDDS	Binary indicator for lipid lowering medication with at least one prescription within 3 months prior to index date, defined using drug use	cov_lipid_meds
anticoagulation	primary care medications	WDDS	Binary indicator for anticoagulation medication with at least one prescription within 3 months prior to index date, defined using drug use	cov_anticoagulation_meds
combined oral contraceptive pill	primary care medications	WDDS	Binary indicator for COCP medication with at least one prescription within 3 months prior to index date, defined using drug use	cov_cocp_meds
blood pressure lowering	primary care medications	WDDS	Binary indicator for bp lowering medication with at least one prescription within 3 months prior to index date, defined using drug use	cov_ever_icvt
hormone replacement therapy	primary care medications	WDDS	Binary indicator for HRT medication with at least one prescription within 3 months prior to index date, defined using drug use	cov_hrt_meds

Variable	Data Sources (NHS England)	Data Sources (SAIL Databank)	Description	Variable name in analysis code
Past history of disease				
acute myocardial infection	GDPPR, HES APC	WLGP, PEDW	Binary indicator for acute myocardial infarction prior to index date, defined using condition diagnosis code only	cov_ever_ami
embolism	GDPPR, HES APC	WLGP, PEDW	Binary indicator for pulmonary embolism or DVT prior to index date, defined using condition diagnosis code only	cov_ever_pe_vt
intracranial venous thrombosis	GDPPR, HES APC	WLGP, PEDW	Binary indicator for ICVT prior to index date, defined using condition diagnosis code only	cov_ever_icvt
any stroke	GDPPR, HES APC	WLGP, PEDW	Binary indicator for stroke (ischaemic stroke, intracranial haemorrhage, or stroke of unknown type) prior to index date, defined using condition diagnosis code only	cov_ever_all_stroke
thrombophilia	GDPPR, HES APC	WLGP, PEDW	Binary indicator for thrombophilia prior to index date, defined using condition diagnosis code only	cov_ever_thrombophilia
thrombocytopenia, TTP	GDPPR, HES APC	WLGP, PEDW	Binary indicator for thrombocytopenia prior to index date, defined using condition diagnosis code only	cov_ever_tcp
dementia	GDPPR, HES APC	WLGP, PEDW	Binary indicator for dementia prior to index date, defined using condition diagnosis code only	cov_ever_dementia
liver disease	GDPPR, HES APC	WLGP, PEDW	Binary indicator for liver disease prior to index date, defined using condition diagnosis code only	cov_ever_liver_disease
chronic kidney disease	GDPPR, HES APC	WLGP, PEDW	Binary indicator for chronic kidney disease prior to index date, defined using condition diagnosis code only	cov_ever_ckd
cancer	GDPPR, HES APC	WLGP, PEDW	Binary indicator for cancer prior to index date, defined using condition diagnosis code only	cov_ever_cancer
hypertension	GDPPR, HES APC, primary care medications	WLGP, PEDW, WDDS	Binary indicator for hypertension prior to index date, defined using either condition diagnosis code or drug use	cov_ever_hypertension
diabetes	GDPPR, HES APC, primary care medications	WLGP, PEDW, WDDS	Binary indicator for diabetes prior to index date, defined using either condition diagnosis code or drug use	cov_ever_diabetes
obesity	GDPPR, HES APC	WLGP, PEDW	Binary indicator for obesity prior to index date, defined using either condition diagnosis code code or measurement	cov_ever_obesity
depression	GDPPR, HES APC	WLGP, PEDW	Binary indicator for depression prior to index date, defined using condition diagnosis code only	cov_ever_depression
COPD	GDPPR, HES APC	WLGP, PEDW	Binary indicator for chronic obstructive pulmonary disease prior to index date, defined using condition diagnosis code only	cov_ever_copd
number of unique disorders	GDPPR	WLGP	Number of consultations for different ailments/conditions/diseases in the year prior to index date	cov_n_disorder
disseminated	GDPPR, HES APC	WLGP, PEDW	Binary indicator for disseminated intravascular coagulation prior to index date,	cov_ever_other_arterial_e

Variable	Data Sources (NHS England)	Data Sources (SAIL Databank)	Description	Variable name in analysis code
intravascular coagulation			defined using condition diagnosis code only	mbolism
mesenteric thrombus	GDPPR, HES APC	WLGP, PEDW	Binary indicator for mesenteric thrombus prior to index date, defined using condition diagnosis code only	cov_ever_dic
artery dissection	GDPPR, HES APC	WLGP, PEDW	Binary indicator for artery dissection prior to index date, defined using condition diagnosis code only	cov_ever_mesenteric_thrombus
life threatening arrhythmias	GDPPR, HES APC	WLGP, PEDW	Binary indicator for life threatening arrhythmias prior to index date, defined using condition diagnosis code only	cov_ever_artery_dissect
cardiomyopathy	GDPPR, HES APC	WLGP, PEDW	Binary indicator for cardiomyopathy prior to index date, defined using condition diagnosis code only	cov_ever_life_arrhythmia
heart failure	GDPPR, HES APC	WLGP, PEDW	Binary indicator for heart failure prior to index date, defined using condition diagnosis code only	cov_ever_cardiomyopathy
pericarditis	GDPPR, HES APC	WLGP, PEDW	Binary indicator for pericarditis prior to index date, defined using condition diagnosis code only	cov_ever_hf
myocarditis	GDPPR, HES APC	WLGP, PEDW	Binary indicator for myocarditis prior to index date, defined using condition diagnosis code only	cov_ever_pericarditis
major surgery in the last year	HES APC	PEDW	Binary indicator for major surgery within a year prior to index date, defined using condition diagnosis code only	cov_ever_myocarditis

547 Acronyms: GDPPR (General Practice Extraction Service (GPES) Data for Pandemic Planning and Research), HES (Hospital Episode Statistics), APC (Admitted Patient Care), AE (Accident and Emergency), WDS (Welsh Demographic Service Dataset), ADDE (Annual District Death Extract), ADDD (Annual District Death Daily), CDDS (COVID-19 Consolidated Deaths), CCDS (Critical Care Dataset), CVVD (Covid Vaccination Dataset), EDDS (Emergency Department Dataset), ICNC (Intensive Care National Audit and Research Centre - Covid19), MIDS (Maternity Indicators Dataset), NCCH (National Community Child Health), OPRD (Outpatient Referral), PEDW (Patient Episode Dataset for Wales), WASD (Welsh Ambulance Services NHS Trust), WLGP (Welsh Longitudinal GP Dataset - Welsh Primary Care), WDDS (Welsh Dispensing Dataset).

551 **Supplementary Table 4. Number of patients analysed in the Welsh SAIL Databank and the number**
 552 **of people (risk per 100,000 during follow up) who were and were not hospitalised within 28 days**
 553 **of diagnosis of COVID-19.**

Characteristic	All	Diagnosed with COVID-19	
		Hospitalised N (per 100,000)	Non-hospitalised N (per 100,000)
All	2,615,854	12,051 (460.7)	66,661 (2,548.3)
Sex			
Male	1,297,835	6,124 (471.9)	28,274 (2,178.6)
Female	1,318,019	5,927 (449.7)	38,387 (2,912.5)
Age in decades			
18-29	480,489	333 (69.3)	17,881 (3721.4)
30-39	416,955	414 (99.3)	12,649 (3033.7)
40-49	395,768	740 (187)	12,401 (3133.4)
50-59	458,138	1,329 (290.1)	12,648 (2760.7)
60-69	379,681	1,778 (468.3)	5,580 (1469.7)
70-79	309,633	3,022 (976)	2,702 (872.6)
80-89	144,198	3,337 (2314.2)	1,921 (1332.2)
90+	30,992	1,098 (3542.8)	879 (2836.2)
Ethnicity			
Asian or Asian British	42,574	151 (354.7)	1,544 (3626.6)
Black or Black British	11,925	36 (301.9)	393 (3295.6)
Missing	579,378	1,522 (262.7)	13,470 (2324.9)
Mixed	15,931	47 (295)	435 (2730.5)
Other Ethnic Groups	15,119	38 (251.3)	423 (2797.8)
White	1,950,926	10,257 (525.8)	50,396 (2583.2)
Index of Multiple Deprivation			
1 (most deprived)	478,172	2,815 (588.7)	14,993 (3135.5)
2	485,212	2,574 (530.5)	14,718 (3033.3)
3	492,738	2,011 (408.1)	10,947 (2221.7)
4	489,763	2,007 (409.8)	9,998 (2041.4)
5 (least deprived)	494,009	1,968 (398.4)	11,510 (2329.9)
Missing	175,960	676 (384.2)	4,495 (2554.6)
Smoking status			
Current	560,733	2,100 (374.5)	11,634 (2074.8)
Former	160,266	1,439 (897.9)	3,398 (2120.2)
Missing	513,315	1,974 (384.6)	10,126 (1972.7)
Never	1,381,540	6,538 (473.2)	41,503 (3004.1)
Medical history			
Arterial event(s)	120,085	2,575 (2,144.3)	2,097 (1,746.3)
Venous event(s)	38,072	732 (1,922.7)	807 (2,119.7)
Number of medications			
0	1,079,924	1,268 (117.4)	28,028 (2,595.4)
1-5	1,367,038	7,011 (512.9)	35,035 (2,562.8)
6+	168,891	3,772 (2,233.4)	3,598 (2,130.4)
Number of diagnosis			
0	2,219,698	6,851 (308.6)	57,853 (2,606.3)
1-5	248,255	3,501 (1,410.2)	5,801 (2,336.7)
6+	147,900	1,699 (1,148.7)	3,007 (2,033.1)

554

555

556 **Supplementary Table 5. Hazard ratios (95% CI) compared with no COVID-19 for different arterial thromboses (acute myocardial infarction and ischaemic**
 557 **stroke), venous thromboembolism events (pulmonary embolism and deep vein thrombosis) and other vascular events, according to time since diagnosis**
 558 **of COVID-19. All results are maximally adjusted unless otherwise stated.**

	Weeks since diagnosis of COVID-19						
	1	2	3-4	5-8	9-12	13-26	27-49
Acute myocardial infarction							
All	17.2 (16.3-18.1)	3.37 (2.99-3.80)	2.37 (2.12-2.64)	1.57 (1.41-1.76)	1.44 (1.26-1.65)	1.17 (1.07-1.29)	1.21 (1.03-1.41)
All, unadjusted	22.1 (21.0-23.2)	4.31 (3.82-4.87)	2.99 (2.68-3.34)	2.03 (1.82-2.27)	1.97 (1.72-2.26)	1.68 (1.53-1.84)	1.75 (1.50-2.05)
Hospitalised COVID-19*	13.7 (12.3-15.3)	6.64 (5.58-7.89)	4.28 (3.60-5.09)	2.42 (2.00-2.92)	1.70 (1.32-2.19)	1.44 (1.23-1.68)	1.39 (1.12-1.72)
Non-hospitalised COVID-19*	17.9 (16.9-19.0)	2.19 (1.85-2.60)	1.79 (1.55-2.06)	1.31 (1.15-1.51)	1.37 (1.16-1.61)	1.06 (0.94-1.19)	1.03 (0.83-1.28)
Ischaemic stroke							
All	23.0 (22.0-24.1)	4.22 (3.78-4.72)	3.17 (2.88-3.50)	2.47 (2.25-2.70)	1.92 (1.70-2.17)	1.58 (1.45-1.71)	1.62 (1.42-1.86)
All, unadjusted	28.1 (26.8-29.4)	5.08 (4.54-5.67)	3.78 (3.42-4.16)	3.02 (2.75-3.31)	2.43 (2.15-2.74)	2.03 (1.87-2.21)	2.15 (1.88-2.47)
Hospitalised COVID-19	15.3 (13.9-16.9)	6.84 (5.79-8.09)	5.87 (5.07-6.80)	4.10 (3.54-4.75)	2.47 (2.01-3.04)	1.64 (1.42-1.90)	1.62 (1.33-1.98)
Non-hospitalised COVID-19	23.2 (22.1-24.4)	2.86 (2.46-3.32)	2.10 (1.84-2.39)	1.74 (1.54-1.95)	1.50 (1.30-1.74)	1.35 (1.22-1.49)	1.33 (1.10-1.59)
Deep vein thrombosis							
All	10.8 (9.32-12.5)	4.00 (3.10-5.15)	4.80 (4.03-5.73)	3.20 (2.68-3.82)	2.55 (2.01-3.25)	1.95 (1.65-2.32)	1.99 (1.49-2.65)
All, unadjusted	12.3 (10.6-14.3)	4.56 (3.54-5.88)	5.47 (4.59-6.52)	3.71 (3.11-4.43)	3.12 (2.45-3.97)	2.48 (2.09-2.94)	2.61 (1.96-3.48)
Hospitalised COVID-19	6.44 (4.28-9.70)	5.03 (3.03-8.35)	6.20 (4.33-8.88)	7.29 (5.56-9.56)	4.20 (2.83-6.22)	2.42 (1.81-3.22)	1.89 (1.19-3.00)
Non-hospitalised COVID-19	11.3 (9.65-13.2)	3.50 (2.61-4.69)	4.23 (3.46-5.17)	2.18 (1.73-2.75)	1.95 (1.44-2.64)	1.64 (1.33-2.03)	1.88 (1.31-2.71)
Pulmonary embolism							
All	33.2 (30.7-35.9)	9.97 (8.57-11.6)	10.5 (9.44-11.8)	5.55 (4.91-6.27)	3.22 (2.66-3.90)	2.41 (2.10-2.76)	1.61 (1.23-2.12)
All, unadjusted	39.7 (36.7-42.9)	11.7 (10.1-13.7)	12.5 (11.2-14.0)	6.76 (5.98-7.63)	4.11 (3.39-4.97)	3.17 (2.76-3.63)	2.22 (1.69-2.92)
Hospitalised COVID-19	19.3 (15.7-23.6)	16.6 (13.1-21.1)	21.0 (17.8-24.9)	14.4 (12.2-17.0)	5.67 (4.23-7.60)	2.76 (2.19-3.48)	1.40 (0.90-2.18)
Non-hospitalised COVID-19	34.5 (31.7-37.5)	7.06 (5.80-8.58)	7.16 (6.21-8.26)	3.07 (2.57-3.67)	2.27 (1.76-2.92)	2.08 (1.76-2.47)	1.60 (1.13-2.27)
Haemorrhagic stroke (intracerebral or subarachnoid haemorrhage)							
All	31.7 (28.6-35.2)	2.83 (1.97-4.05)	1.92 (1.39-2.67)	1.86 (1.41-2.45)	1.99 (1.43-2.76)	1.57 (1.27-1.95)	1.80 (1.29-2.50)
All, unadjusted	40.2 (37.3-43.3)	3.51 (2.71-4.54)	2.43 (1.93-3.07)	2.28 (1.87-2.78)	2.78 (2.19-3.52)	2.09 (1.79-2.44)	2.54 (2.01-3.20)
Hospitalised COVID-19	12.4 (8.94-17.2)	3.97 (1.78-8.84)	2.41 (1.21-4.83)	2.22 (1.23-4.01)	4.85 (3.01-7.81)	1.81 (1.19-2.75)	1.17 (0.59-2.35)
Non-hospitalised COVID-19	37.3 (33.4-41.6)	2.46 (1.60-3.78)	1.74 (1.18-2.56)	1.64 (1.18-2.28)	1.21 (0.76-1.92)	1.46 (1.13-1.89)	2.25 (1.55-3.27)
Transient ischaemic attack							
All	7.79 (6.99-8.68)	2.05 (1.64-2.56)	1.44 (1.18-1.76)	1.41 (1.19-1.66)	1.39 (1.15-1.69)	1.17 (1.03-1.34)	1.38 (1.13-1.69)
All, unadjusted	9.23 (8.54-9.97)	2.43 (2.08-2.85)	1.68 (1.46-1.94)	1.71 (1.51-1.92)	1.79 (1.56-2.05)	1.53 (1.39-1.67)	1.80 (1.56-2.08)
Hospitalised COVID-19	5.82 (4.54-7.45)	1.97 (1.22-3.17)	1.75 (1.15-2.67)	2.02 (1.47-2.77)	1.85 (1.27-2.70)	1.24 (0.97-1.58)	1.60 (1.19-2.16)
Non-hospitalised COVID-19	8.44 (7.48-9.52)	2.07 (1.61-2.66)	1.34 (1.06-1.69)	1.27 (1.04-1.54)	1.32 (1.05-1.66)	1.13 (0.97-1.32)	1.20 (0.91-1.58)

	Weeks since diagnosis of COVID-19						
	1	2	3-4	5-8	9-12	13-26	27-49
Angina							
All	6.37 (5.94-6.83)	1.97 (1.73-2.25)	1.72 (1.55-1.92)	1.45 (1.32-1.60)	1.22 (1.07-1.38)	1.08 (1.00-1.18)	1.07 (0.93-1.23)
All, unadjusted	8.12 (7.73-8.53)	2.47 (2.25-2.72)	2.14 (1.98-2.31)	1.84 (1.72-1.98)	1.62 (1.48-1.77)	1.50 (1.41-1.59)	1.53 (1.39-1.69)
Hospitalised COVID-19	5.31 (4.58-6.15)	3.01 (2.42-3.73)	2.58 (2.13-3.12)	1.61 (1.32-1.96)	1.45 (1.14-1.83)	1.13 (0.98-1.31)	0.98 (0.79-1.21)
Non-hospitalised COVID-19	6.72 (6.20-7.28)	1.48 (1.24-1.77)	1.44 (1.26-1.64)	1.40 (1.25-1.56)	1.15 (0.99-1.34)	1.06 (0.96-1.18)	1.17 (0.98-1.41)
Heart failure							
All	9.40 (8.99-9.84)	2.01 (1.81-2.24)	2.04 (1.89-2.21)	1.98 (1.85-2.11)	1.89 (1.74-2.04)	1.42 (1.35-1.50)	1.27 (1.15-1.39)
All, unadjusted	13.8 (13.4-14.3)	2.86 (2.65-3.08)	2.87 (2.71-3.04)	2.85 (2.72-2.99)	2.96 (2.79-3.12)	2.31 (2.22-2.40)	2.19 (2.05-2.34)
Hospitalised COVID-19	8.21 (7.56-8.93)	2.50 (2.10-2.97)	3.27 (2.89-3.70)	3.03 (2.72-3.37)	2.62 (2.30-2.97)	1.86 (1.71-2.02)	1.45 (1.28-1.66)
Non-hospitalised COVID-19	9.92 (9.39-10.5)	1.73 (1.51-1.98)	1.57 (1.41-1.74)	1.62 (1.49-1.76)	1.59 (1.44-1.76)	1.22 (1.13-1.31)	1.10 (0.96-1.26)

559

560 **Supplementary Table 6. Hazard ratios (95% CI) compared with no COVID-19 for first arterial thrombosis, according to time since diagnosis of COVID-19.**
 561 **All results are maximally adjusted unless otherwise stated.**

	Weeks since diagnosis of COVID-19						
	1	2	3-4	5-8	9-12	13-26	27-49
All	21.7 (21.0-22.4)	3.87 (3.58-4.19)	2.80 (2.61-3.01)	2.00 (1.87-2.14)	1.58 (1.45-1.73)	1.34 (1.27-1.43)	1.34 (1.21-1.48)
All, unadjusted	27.9 (27.0-28.8)	4.90 (4.53-5.30)	3.50 (3.27-3.76)	2.57 (2.40-2.75)	2.14 (1.96-2.34)	1.88 (1.77-2.00)	1.92 (1.73-2.12)
Hospitalised COVID-19 ¹	14.2 (13.2-15.3)	6.60 (5.85-7.44)	4.97 (4.43-5.56)	3.25 (2.90-3.66)	2.00 (1.70-2.36)	1.50 (1.35-1.68)	1.46 (1.26-1.70)
Non-hospitalised COVID-19	22.0 (21.2-22.9)	2.65 (2.37-2.96)	2.03 (1.84-2.23)	1.58 (1.45-1.73)	1.42 (1.27-1.59)	1.24 (1.15-1.34)	1.21 (1.05-1.40)
Prior history of event		5.68 (5.40-5.98)			1.42 (1.34-1.51)		
No prior history of event		10.6 (10.2-11.0)			1.72 (1.63-1.82)		
Age <40 years	16.7 (12.7-22.0)	3.30 (1.77-6.16)	1.31 (0.62-2.75)	1.07 (0.53-2.14)	0.90 (0.33-2.40)	1.56 (0.93-2.61)	0.94 (0.30-2.93)
Age 40-59 years	19.3 (17.8-21.0)	3.36 (2.75-4.12)	2.72 (2.30-3.22)	1.92 (1.62-2.28)	1.77 (1.41-2.22)	1.39 (1.18-1.64)	1.86 (1.48-2.35)
Age 60-79 years	26.8 (25.6-28.2)	4.61 (4.09-5.19)	3.03 (2.71-3.39)	2.20 (1.98-2.45)	1.61 (1.38-1.87)	1.38 (1.25-1.53)	1.39 (1.18-1.64)
Age 80+ years	18.1 (17.2-19.0)	3.40 (3.00-3.85)	2.67 (2.39-2.98)	1.89 (1.70-2.10)	1.54 (1.35-1.75)	1.30 (1.19-1.42)	1.12 (0.96-1.31)
Females	20.5 (19.5-21.5)	3.36 (2.97-3.81)	2.61 (2.35-2.91)	1.91 (1.72-2.11)	1.55 (1.36-1.77)	1.27 (1.16-1.38)	1.19 (1.02-1.39)
Males	22.9 (21.9-23.8)	4.33 (3.92-4.79)	3.00 (2.73-3.29)	2.10 (1.91-2.30)	1.64 (1.45-1.86)	1.43 (1.32-1.55)	1.50 (1.31-1.71)
White		7.66 (7.42-7.92)			1.47 (1.40-1.53)		
Black or Black British		10.4 (8.70-12.5)			1.96 (1.60-2.41)		
Asian or Asian British		9.35 (8.48-10.3)			1.64 (1.43-1.89)		
Other ethnic groups		9.04 (6.84-12.0)			1.97 (1.39-2.79)		
Mixed ethnicity		8.27 (5.88-11.6)			1.24 (0.77-1.99)		

562


563

564 **Supplementary Table 7. Hazard ratios (95% CI) compared with no COVID-19 for first venous thromboembolism, according to time since diagnosis of**
 565 **COVID-19. All results are maximally adjusted unless otherwise stated.**

	Weeks since diagnosis of COVID-19						
	1	2	3-4	5-8	9-12	13-26	27-49
All	33.2 (31.3-35.2)	8.52 (7.59-9.58)	7.95 (7.28-8.68)	4.26 (3.86-4.69)	2.96 (2.58-3.41)	2.20 (1.99-2.44)	1.80 (1.50-2.17)
All, unadjusted	40.3 (38.0-42.7)	10.1 (9.03-11.4)	9.44 (8.65-10.3)	5.19 (4.71-5.72)	3.79 (3.29-4.36)	2.92 (2.64-3.23)	2.49 (2.07-3.00)
Hospitalised COVID-19	14.5 (12.2-17.4)	11.5 (9.22-14.2)	14.3 (12.3-16.7)	11.2 (9.72-12.9)	5.40 (4.31-6.77)	2.63 (2.19-3.14)	1.57 (1.14-2.16)
Non-hospitalised COVID-19	24.4 (22.7-26.3)	5.46 (4.66-6.40)	6.05 (5.39-6.78)	2.56 (2.22-2.95)	2.22 (1.84-2.68)	1.98 (1.74-2.25)	1.77 (1.38-2.27)
Prior history of event		6.21 (5.30-7.27)				1.72 (1.45-2.05)	
No prior history of event		12.1 (11.5-12.8)				2.87 (2.68-3.08)	
Age <40 years	18.6 (14.9-23.1)	5.95 (4.04-8.76)	5.62 (4.16-7.58)	2.94 (2.06-4.18)	2.09 (1.21-3.61)	2.98 (2.17-4.11)	2.85 (1.61-5.05)
Age 40-59 years	31.8 (28.3-35.7)	11.8 (9.80-14.3)	9.61 (8.26-11.2)	3.68 (3.00-4.52)	2.44 (1.78-3.36)	2.18 (1.76-2.70)	1.68 (1.11-2.53)
Age 60-79 years	42.2 (38.5-46.2)	9.27 (7.64-11.2)	9.06 (7.88-10.4)	5.07 (4.34-5.91)	3.57 (2.86-4.45)	2.40 (2.03-2.84)	2.10 (1.56-2.82)
Age 80+ years	27.9 (24.7-31.5)	3.75 (2.76-5.10)	4.81 (3.90-5.93)	4.23 (3.53-5.06)	2.91 (2.29-3.71)	1.81 (1.51-2.17)	1.38 (0.97-1.96)
Females	29.7 (27.3-32.3)	6.84 (5.77-8.12)	6.87 (6.04-7.81)	4.22 (3.70-4.82)	3.00 (2.49-3.63)	2.08 (1.81-2.39)	1.91 (1.49-2.44)
Males	38.2 (35.2-41.5)	11.0 (9.41-12.9)	9.50 (8.43-10.7)	4.40 (3.81-5.09)	3.08 (2.49-3.79)	2.41 (2.08-2.80)	1.76 (1.32-2.34)
White		10.1 (9.56-10.7)				2.49 (2.32-2.66)	
Black or Black British		18.0 (14.2-22.8)				2.68 (1.94-3.70)	
Asian or Asian British		17.6 (14.1-21.8)				4.05 (3.09-5.31)	
Other ethnic groups		15.9 (9.13-27.8)				5.62 (3.28-9.63)	
Mixed ethnicity		15.7 (9.78-25.1)				2.52 (1.29-4.93)	


566

567 **Supplementary Figure 1. Maximally adjusted hazard ratios (log scale) for different arterial thrombotic,**
 568 **and venous thromboembolic and other vascular events by time since diagnosis of COVID-19, separately**
 569 **for hospitalised and non-hospitalised COVID-19.**



570

571 **Supplementary Figure 2. Estimated absolute increase in risk of arterial and venous events over time since diagnosis of COVID-19, compared with no**
 572 **COVID-19 diagnosis, after excluding the risk during the first 28 days since diagnosis**



573